UK Approves Groundbreaking CRISPR-Based Gene Therapy For Sickle Cell Disease And Thalassemia

Gene therapy takes a giant leap forward as Exa-cel becomes the world ’s first CRISPR/Cas9 gene-edited therapy approved to treat sickle cell disease and thalassemia.

Source: Forbes.com Healthcare News - November 18, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news